about
CARD9-Dependent Neutrophil Recruitment Protects against Fungal Invasion of the Central Nervous SystemPerformance Characteristics and Validation of Next-Generation Sequencing for Human Leucocyte Antigen Typing.Clinically focused exome sequencing identifies an homozygous mutation that confers DOCK8 deficiency.Clinical validation of NGS technology for HLA: An early adopter's perspective.Identification of a novel allele: DQB1*06:127 in Hispanic sisters.HLAProfiler utilizes k-mer profiles to improve HLA calling accuracy for rare and common alleles in RNA-seq data.A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.Regulation of maturation and activating potential in CD8+ versus CD8- dendritic cells following in vivo infection with vaccinia virus.Two cases of asymptomatic massive fetomaternal hemorrhage.Buccal swab genomic DNA fragmentation predicts likelihood of successful HLA genotyping by next-generation sequencing.The Past, Present, and Future of HLA Typing in TransplantationGlomerular C4d deposits can mark structural capillary wall remodelling in thrombotic microangiopathy and transplant glomerulopathy: C4d beyond active antibody-mediated injury: a retrospective studyInfluence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant PatientsDevelopment of data-driven models for the flow cytometric crossmatchSuitability of dried DNA for long-range PCR amplification and HLA typing by next-generation sequencingQuality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics WorkshopCharacteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantationHLA alleles and haplotypes observed in 263 US familiesPerformance of a multiplexed amplicon-based next-generation sequencing assay for HLA typingThe receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
P50
Q27316717-7380F0FC-2F79-4064-87D6-B8A7301F15A7Q36067440-24BC897D-E1EE-47DF-AE1F-FEBDF3E532CAQ36493942-E7C56E2A-426B-4167-8ED6-47653F789987Q38877845-AFD476A5-C2CF-4F43-9835-FD99C250760DQ40528411-FE27BD40-053F-4851-976E-620124C02E24Q42063952-653F70B1-276A-486E-A8A7-631B26153C7EQ43121719-FDE586A7-14CA-4821-B519-9D14ABAC0C71Q43210885-F872B4FA-AE23-4926-AFBA-9B1B615A4C1FQ50450670-D4AEBBF6-475C-43E6-8FD6-F2CF35BE3AB6Q50502372-F3906003-E6AF-481E-A71D-A38574A39427Q88956385-30F68FAB-B0C6-4B07-A00C-CC70D487D69AQ89294629-9DB4E1C9-77B2-4223-834C-80B7DF77FF08Q89511371-8BF2692D-0D17-46BB-971C-F8A0775C301CQ90147093-C31EE166-9D17-4CC7-A51A-DC4F849B5423Q90357632-702234E7-9CD7-4619-9A2F-54802FD12AF3Q91433263-77708B4C-0488-4AC4-9298-7CF6B87A5899Q91866757-9FCE57ED-2A0F-48DF-9C4A-073C70673275Q93136943-FE4B2842-6544-405D-9FA6-6E3D233A2826Q93179240-FFFED3B5-C584-4908-A201-BAD9CA3275B7Q96301544-11CD918A-C2DA-4411-B40D-9564647A4973
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Eric T Weimer
@en
Eric T Weimer
@nl
type
label
Eric T Weimer
@en
Eric T Weimer
@nl
prefLabel
Eric T Weimer
@en
Eric T Weimer
@nl
P31
P496
0000-0003-3677-5724